Jul 2021 $1 M Private placement after listing Under $2 million 1
Nephros Inc.: Private sale, Jul 2021 × Investors in this round 1 investor had bought by the notice of Jul 14, 2021: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andrew Astor · Executive Officer, Director Alisa Lask · Director Arthur Amron · Director Malcolm Person · Director Oliver Spandow · Director Thomas Gwydir · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On a merger: “Nephros, Inc. issued 123,981 shares of its common stock to GenArraytion, Inc. as consideration for the acquisition of substantially all of the assets of GenArraytion, Inc.”Signed by Andrew Astor, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 14, 2021. Read the notice at the SEC .
equity SEC May 2019 $2 M Private placement after listing $2 to $10 million 12
Nephros Inc.: Private sale, May 2019 × Investors in this round 12 investors had bought by the notice of May 21, 2019: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $100,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Andrew Astor · Executive Officer Daron Evans · Executive Officer, Director Alisa C. Lask · Director Arthur H. Amron · Director Malcolm C. Persen · Director Oliver C. Spandow · Director Paul A. Mieyal · Director Thomas C. Gwydir · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Anticipated payment of executive officer salaries.”Signed by Daron Evans, Chief Executive Officer. Source: SEC Form D, newest notice filed May 21, 2019. Read the notice at the SEC .
equity SEC Apr 2018 $3 M Private placement after listing $2 to $10 million 13
Nephros Inc.: Private sale, Apr 2018 × Investors in this round 13 investors had bought by the notice of Apr 18, 2018: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $100,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Andrew Astor · Executive Officer Daron Evans · Executive Officer, Director Arthur Amron · Director Malcolm Persen · Director Moshe Pinto · Director Paul Mieyal · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Anticipated payment of executive officer salaries.”Signed by Andrew Astor, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 18, 2018. Read the notice at the SEC .
equity SEC Mar 2017 $2 M Private placement after listing $2 to $10 million 19
Nephros Inc.: Private sale, Mar 2017 × Investors in this round 19 investors had bought by the notice of Mar 27, 2017: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $91,350
Finders' fees none
Paid to its own people $100,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Andrew Astor · Executive Officer Daron Evans · Executive Officer, Director Arthur Amron · Director Malcolm Persen · Director Moshe Pinto · Director Paul Mieyal · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · broker-dealer Maxim Group LLC (CRD 120708) · New York, New York Sold in all US states Remarks in the notice On fees: “In addition, the placement agent received warrants to purchase 81,199 shares of common stock.”On the amounts: “The total offering amount and total amount sold include both common stock and warrants to purchase $1218000 of common stock.”On the use of proceeds: “Anticipated payment of executive officer salaries.”Signed by Daron Evans, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 27, 2017. Read the notice at the SEC .
equity, options SEC Jul 2015 $1 M Private placement after listing Under $2 million 1
Nephros Inc.: Private sale, Jul 2015 × Investors in this round 1 investor had bought by the notice of Sep 18, 2018: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $10 M offered; $9 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $100,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Andrew Astor · Executive Officer Daron Evans · Executive Officer, Director Arthur Amron · Director Malcolm Persen · Director Moshe Pinto · Director Oliver Spandow · Director Paul Mieyal · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Anticipated payment of executive officer salary.”Signed by Daron Evans, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 18, 2018. Read the notice at the SEC .
equity SEC May 2015 $1 M Private placement after listing Under $2 million 26
Nephros Inc.: Private sale, May 2015 × Investors in this round 26 investors had bought by the notice of May 27, 2015: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $2 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $100,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Daron Evans · Executive Officer, Director Arthur Amron · Director Lawrence Centella · Director Malcolm Persen · Director Matthew Rosenberg · Director Paul Mieyal · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Anticipated payment of executive officer salary.”Signed by Daron Evans, Chief Executive Officer. Source: SEC Form D, newest notice filed May 27, 2015. Read the notice at the SEC .
equity, options SEC Jul 2009 $1 M No. 1 Under $2 million 8
Nephros Inc.: Raise no. 1, Jul 2009 × Investors in this round 8 investors had bought by the notice of Aug 7, 2009: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $3 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Ermest A. Elgin, III · Executive Officer Gerald J. Kochanski · Executive Officer Arthur H. Amron · Director Dr. Paul A. Mieyal · Director James S. Scibetta · Director Lawrence J. Centella · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Other than the payment of salaries and other compensation and benefits no officer, director or promoter will receive any payments from the proceeds of this offering.”Signed by Gerald J. Kochanski, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 7, 2009. Read the notice at the SEC .
equity, options SEC